Novartis shares dropped as much as 10% after the drugmaker said an experimental neuromuscular treatment failed a late-stage clinical trial

The failure of a neuromuscular treatment is a blow to the drugmaker’s efforts to revive its growth prospects.

Discover more from RealUS.news

Subscribe now to keep reading and get access to the full archive.

Continue reading